Streetbeat News

Price Targets

IBEX

Piper Sandler analyst Arvind Ramnani has downgraded IBEX (NASDAQ:IBEX) from Overweight to Neutral and set a price target of $17.

Portfolio Pulse from Benzinga Newsdesk

November 10, 2023 | 9:44 am

GLOB

Piper Sandler analyst Arvind Ramnani has maintained an Overweight rating on Globant (NYSE:GLOB) but lowered the price target from $230 to $212.

Portfolio Pulse from Benzinga Newsdesk

November 10, 2023 | 9:39 am

LAW

Piper Sandler analyst Arvind Ramnani has maintained a Neutral rating on CS Disco (NYSE:LAW) and lowered the price target from $9 to $6.5.

Portfolio Pulse from Benzinga Newsdesk

November 10, 2023 | 9:28 am

VEEV

Piper Sandler analyst Brent Bracelin has maintained an Overweight rating on Veeva Systems (VEEV) but lowered the price target from $235 to $200.

Portfolio Pulse from Benzinga Newsdesk

November 10, 2023 | 9:23 am

PHAT

Needham analyst Joseph Stringer has reiterated a 'Buy' rating on Phathom Pharmaceuticals (NASDAQ:PHAT) and maintained a price target of $23.

Portfolio Pulse from Benzinga Newsdesk

November 10, 2023 | 9:16 am

U

Piper Sandler analyst Brent Bracelin has maintained a Neutral rating on Unity Software (NYSE:U) and lowered the price target from $30 to $20.

Portfolio Pulse from Benzinga Newsdesk

November 10, 2023 | 9:13 am

TCNNF

Needham analyst Matt McGinley has maintained a 'Buy' rating on Trulieve Cannabis (OTC:TCNNF) but lowered the price target from $9 to $6.5.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 10:58 pm

RXRX

Needham analyst Gil Blum maintains a 'Buy' rating on Recursion Pharmaceuticals (NASDAQ:RXRX), but lowers the price target from $17 to $15.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 10:56 pm

IKNA

HC Wainwright & Co. analyst Andres Maldonado maintains a 'Buy' rating on Ikena Oncology (NASDAQ:IKNA), but has lowered the price target from $18 to $11.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 10:53 pm

AGL

Truist Securities analyst Jailendra Singh has maintained a 'Buy' rating on Agilon Health (NYSE:AGL) but lowered the price target from $27 to $23.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 10:49 pm